Abstract 156P
Background
The accessibility to drugs recommended by dedicated molecular tumor board (MTB) varies across countries, mainly due to different health insurance policies. In the Czech Republic, reimbursement of comprehensive genomic profiling (CGP) is available to all patients with advanced and pretreated solid tumors with no further therapeutic options, regardless of the type of public health insurance. We present the rate of accessibility to the therapy recommended by MTB and its effectiveness.
Methods
Between February 2021 and June 2023, 309 patients with different advanced and pretreated solid tumors were presented at the MTB at University Hospital Brno. If indicated, tumor tissues were analyzed by use of the combined DNA/RNA sequencing panel (TSO500 assay, Illumina). Additionally to CGP, immunohistochemistry results were also discussed, and MTB recommendations were graded according to the Joint consensus recommendation for reporting genetic variants in cancers (AMP TIER classification).
Results
The CGP was performed in 259 (83.8%) presented patients. Alterations classified as TIER IA/B or IIC were detected in 123 (47.5%) cases. CPS > 1, TMB > 10 mut/Mb or MSI – high status, were detected in 72 (27.8%) cases. Therapy was recommended by MTB in 157 (60.6%) patients. Reimbursement was requested from insurance providers in 54 cases with 41 approvals and 13 refusals (3 received therapy anyway thanks to external funding or covering costs themselves). In another 8 patients, the recommended therapy had already been reimbursed. Progression-free survival 2 (on recommended therapy, PFS2) and 1 (on prior standard therapy, PFS1) ratio > 1.3 was observed in 16 (39%) from 41 evaluable heavily pretreated patients.
Conclusions
In the Czech Republic, CGP in advanced solid tumors is reimbursed regardless of the type of public health insurance. At our university center, 62 patients were indicated to start the recommended therapy by MTB. Reimbursement was secured in 49 (79%) cases. PFS2/PFS1 ratio > 1.3 was not met in 61% of patients. As the main reason we consider the late initiation of molecularly driven therapy in the overall management of our patients (median treatment line was 3).
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Masaryk University Brno.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Hypomethylated immune gene promoters as potential biomarkers in oral and oropharyngeal cancer
Presenter: Petra Anić
Session: Cocktail & Poster Display session
Resources:
Abstract
105P - Implementation of technical improvements in cfMeDIP-Seq library preparation
Presenter: Martina Dameri
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Clinical application of next-generation sequencing in metastatic colorectal cancer (mCRC): Experience from a comprehensive cancer centre
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
108P - Validation and implementation of a large NGS panel to test liquid biopsies from patients with suspected advanced non-small cell lung cancer (NSCLC) in an NHS genomic laboratory for the QuicDNA biomarker study
Presenter: Rachel Dodds
Session: Cocktail & Poster Display session
Resources:
Abstract
109P - A multiomic, single-cell measurable residual disease (scMRD) assay for phasing DNA mutations and surface immunophenotypes
Presenter: Simone Formisano
Session: Cocktail & Poster Display session
Resources:
Abstract
110P - Multicellular three-dimensional tumor spheroid of nasopharyngeal carcinoma
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
111P - Development of digital PCR for accurate measurement of HER2 amplification in 184 gastric cancer patients
Presenter: So Young Kang
Session: Cocktail & Poster Display session
Resources:
Abstract
112P - A novel methylation-sensitive assay for early detection of hepatocellular carcinoma to improve surveillance
Presenter: Jeong Sil Ha
Session: Cocktail & Poster Display session
Resources:
Abstract